Illumina reported robust Q1 2026 results, beating revenue and profit margin expectations through solid demand for its core sequencing platforms and consumables. The company’s acquisition of SomaLogic, completed early in 2026, marks a critical strategic pivot toward proteomics, broadening Illumina’s multiomics capabilities. This diversification complements its genomics portfolio and positions Illumina to capitalize on growing adoption in clinical and applied markets. Financially, Illumina maintains a strong liquidity position alongside a manageable debt profile, supporting ongoing R&D investment and share repurchase programs amid competitive pressures and integration risks.